Limbic Stem Cells & Exosomes
Overview
At the heart of our regenerative ophthalmology solutions lies Limbic Stem Cells (LSCs) and Exosome Technology, developed through a groundbreaking collaboration. This innovative technology combines the regenerative power of LSCs and exosomes to deliver cutting-edge therapies for some of the most challenging eye conditions.
A Strategic Partnership
Through an exclusive partnership with 3D Biotech, YD Biopharma holds the global rights to market and distribute these advanced investigational solutions. While 3D Biotech focuses on the development and production of the proprietary technology, YD Biopharma leads efforts to advance these therapies toward broader patient access worldwide.
Exclusive Distribution Rights
YD Biopharma holds the exclusive global marketing and distribution rights for 3D Biotech’s investigational technologies, providing access to innovative therapeutic platforms.
Superior Production Technology
The patented technology enables a 20-fold increase in cell growth within 5 days in preclinical evaluations, offering the potential to reduce production timelines and support broader treatment accessibility.
Demonstrated Potential for Safety and Compatibility
Limbal stem cells (LSCs) have demonstrated the potential to reduce immune rejection risks, supporting the development of safer and more compatible therapeutic approaches.
Scalable and Reliable Supply
3D Biotech’s advanced manufacturing capabilities are designed to deliver consistent, high-quality supply, supporting YD Biopharma’s efforts to meet future global demand.
Experience the Advantage of Innovation
Partner with YD Biopharma to access investigational limbal stem cell and exosome-based therapeutic platforms, developed through our exclusive collaboration with 3D Biotech. Together, we are advancing the future of vision care.
Future Vision
With exclusive access to 3D Biotech’s advanced technology, YD Biopharma is committed to advancing the field of regenerative vision care. Our goal is to develop innovative therapeutic platforms aimed at expanding future access to patients worldwide, supporting improvements in quality of life and contributing to the evolution of ophthalmology standards.
